Industry should be ready for reporting deadline, warns Esma

Rodrigo Buenaventura at Esma
Rodrigo Buenaventura, Esma

Some buy-side firms might miss a looming deadline for trade reporting of over-the-counter derivatives in Europe but market participants have had plenty of time to prepare and should be ready for February 12, a senior official at the European Securities and Markets Authority (Esma) has warned.

Under the European Market Infrastructure Regulation (Emir), trade reporting begins 90 days after the first trade repositories have been approved. Following Esma's approval of the first batch of repositories in November, market participants have been scrambling to get the necessary infrastructure in place to begin reporting on February 12.

"We are talking here about potentially hundreds of thousands of counterparties, some of whom, like small and medium-sized corporates, have never been subject to this sort of financial regulation before. One should not be surprised that a small percentage of those may not be ready by February 12," says Rodrigo Buenaventura, head of the markets division at Esma in Paris, speaking exclusively to FX Week.

While mandatory trade reporting began in the US under the Dodd-Frank Act early last year, it is more complex in Europe as Emir states that both counterparties to a trade are responsible for reporting, which means a single unique trade identifier (UTI) must be generated and reported by both the bank and its client. With the deadline now less than five weeks away, many participants expect compliance to be patchy.

"The chances of all participants being ready for reporting on February 12 are nil. Absolutely nil. That has been obvious for a long time, but it's anyone's guess what will happen when the date comes around," says an official at one market infrastructure provider.

While Esma has shown no inclination to move the deadline, it will be up to national regulators to determine how they wish to address non-compliance in the early days. But despite the complexities and challenges, Buenaventura insists the industry has had sufficient time to prepare and Esma has done its part to support those preparations.

"Some trade reporting regulations under Emir have been in place for over 13 months, so market participants have known about these obligations for quite some time. We have conducted a significant amount of outreach to participants on the sell side and buy side to inform them of the changes," he says.

In the FX market, the major sticking point has been the generation of UTIs, which must be approved for each specific trade by both counterparties and then passed on to the trade repository. With a multitude of repositories set to operate in Europe, arriving at a consistent system for all participants has been a tricky process. Esma last year rejected a proposal made by the Global Financial Markets Association and the industry continues to grapple with the challenge.

"We have analysed different industry initiatives, but we have not decided to endorse a particular way to construct a UTI as the only way to construct it," says Buenaventura. "We have deliberately left that up to the industry, which has had 13 months to develop workable solutions. We recognise that UTI generation in the FX market is more complicated – the number of non-financial companies involved in reporting, and the absence of a central hub or CCP, makes it a big challenge. We have not ruled out issuing further guidance on this matter before or after February 12."

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact customer services - www.fx-markets.com/static/contact-us, or view our subscription options here: https://subscriptions.fx-markets.com/subscribe

You are currently unable to copy this content. Please contact info@fx-markets.com to find out more.

You need to sign in to use this feature. If you don’t have a FX Markets account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: